The Medicines Company and RNA biotech partner Alnylam have set out a new, large late-stage test for their next-gen anticholesterol candidate inclisiran, which…

AstraZeneca has taken another step toward the completion of its new headquarters and R&D hub in Cambridge, U.K.

Amgen has firmed up its lead in the race to bring the first CGRP inhibitor to market for migraine after presenting positive results from its two phase 3 trials.

Otsuka Pharmaceutical has expanded its anemia pact with Akebia Therapeutics.

Circassia CEO Steve Harris has defended the running of the company’s allergy trials, stating nothing could have been done better.

Sienna Biopharmaceuticals has raised $40 million to advance its pipeline of clinical-phase aesthetic and dermatology assets.

It’s been a torrid few weeks for pressured OncoMed with trial woes compounded by partners walking away. Now, after hinting at cuts earlier this month, the…

After Jefferies analyst Biren Amin said last night that he thought Novartis would be presenting its midstage CAR-T blood cancer data from Juliet at a Swiss…

European pharma leaders have drafted an open letter calling for strenuous efforts to avoid disruption at the EMA post-Brexit.